The Board of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the following board resolutions have been passed with effect
from 1 June 2022: Mr. Wang Kexin has been appointed as the co-chairman of the ninth session of the Board; Ms. Guan Xiaohui has been re-appointed as the vice chairman of the ninth session of the Board; Mr. Wen Deyong has been appointed as the chief executive officer of the Company; Mr. Wu Yifang has been appointed as the chairman of the strategic committee of the ninth session of the Board. Mr. Wang Kexin, aged 58, is an executive Director and the co-chairman of the Board and is a director of certain subsidiaries of the Group. He joined the Group in June 2010 and served as the vice president of the Company from July 2011 to July 2016, a senior vice president of the Company from July 2016 to October 2020 and the co-president and chief investment officer of the Company from October 2020 to January 2022, has served as an executive Director since December 2021, served as a vice chairman of the Company from January 2022 to June 2022, and has served as the co-chairman of the Company since June 2022. He is currently a vice president of Fosun International Limited, a company listed on the The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange'). Prior to joining the Group, he served as the deputy general manager of Haihong Holdings Pharmaceutical E-commerce Co., Ltd., the marketing director of Kunming Pharmaceutical (Group) Co., Ltd, a company listed on Shanghai Stock Exchange, the general manager of Kunming Pharmaceutical Sales Co., Ltd., the general manager of Beijing Huali Jiuzhou Pharmaceutical Co., Ltd., the vice president of Chongqing Huali Pharmaceutical Co., Ltd., a company previously listed on Shenzhen Stock Exchange, and the chairman of Beijing Tianren Hexin Pharmaceutical Management Co., Ltd. He obtained a bachelor's degree in pharmacy from Shenyang Pharmaceutical College. The Board announced that Mr. Wu Yifang has been appointed as the chairman of the strategic committee of the ninth session of the Board with effect from 1 June 2022. Mr. Chen Qiyu no longer serves as the chairman of the strategic committee but remains as a member of the strategic committee with effect from 1 June 2022. Save as disclosed above, the appointments of the members of the Board committees of the ninth session remain the same as those of the eighth session of the Board.